KromaTiD provides innovative solutions for the discovery, detection and quantification of genomic structural variations. With our dGH™ platform, we are able to observe gene editing-associated rearrangements in their chromosomal structural context. The data is complementary to sequencing and our assays provide researchers and innovators in gene editing with an additional dimension of data to support optimization of process variables, quantitation of structural off-target effects, and tracking of durable genomic changes over time.
Location: United States
Employees: 11-50
Total raised: $10M
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | First Capi... | firstcapit... |
| - | BroadOak C... | broadoak.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.08.2025 | Series C | $8M | BroadOak C... |
| 28.04.2021 | - | $2M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.06.2026 | Longmont gene-analysis firm Kromatid elevates new leader | Getting your Trinity Audio player ready... Longmont-based gene-analysis company Kromatid Inc. recently promoted Matthew Hemstreet to CEO, a role he takes over from interim chief Terry Opgenorth. Already have an account Log In This article i... |
| 22.08.2025 | KROMATID: $8 Million Series C Raised For Genomic Structural Analysis | KROMATID, a pioneering force in next-generation genomic structural analysis, announced the completion of its Series C funding round, which has raised a total of $8 million, significantly exceeding its initial capital goals. The latest tranc... |
| 22.08.2025 | KROMATID Announces $8M Series C Round | BOULDER, CO, KROMATID, a leader in next-generation genomic structural analysis, has announced the successful close of its Series C funding round. >> Click here for more funding data on KROMATID >> To export KROMATID funding dat... |
| 28.04.2021 | KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners | |
| 11.02.2021 | KromaTiD Announces the Addition of James Chomas to the Board of Directors | |
| 13.08.2019 | KromaTiD Closes Series A Financing Round | KromaTiD, Inc., a Longmont, Colorado-based maker of a directional Genomic Hybridization (dGHTM) platform, completed its Series A financing round. First Capital Ventures made the investment, whose amount was not disclosed. The company intend... |
| 19.07.2011 | Variation Biotech Raises $7.8M in Debt Funding | Vaccine developer Variation Biotechnologies Inc. has raised a combined $7.8 million in a pair of debt financings. >> Click here for more funding data on Variation Biotech >> To export Variation Biotech funding data to PDF an... |
| - | Kromatid | “KROMATID delivers high-quality genomic integrity data through single-cell analysis, enhancing safety and efficacy in cell and gene therapy development for better patient outcomes.” |